ReviewPharmacoEconomics2014
When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES.
Review in PharmacoEconomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Patient-level simulation models in cancer care: a systematic review.Frontiers in public health · 2025Pooled it
- Pooled it
- Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology.PharmacoEconomics - open · 2021Pooled it
- Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions.PharmacoEconomics · 2021Pooled it
- Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment.PharmacoEconomics · 2017Pooled it
- Comparing the Influence of Heterogeneity on Model Outcomes in Individual-Level and Cohort Simulations: An Exploratory Simulation Study.PharmacoEconomics · 2026Article
- Productivity-adjusted life year loss among the late middle-aged adults in China.Communications medicine · 2025Article
- Discrete Event Simulation in R using the 'Simmer' Package for Health Economic Modelling: A Tutorial and Illustration in Colon Cancer.Applied health economics and health policy · 2025Review
- Using Linked Health Service Data in Multimodal Modeling of Kidney Transplant Waitlist Outcomes: Protocol for the Maximizing Organ Donor Utility Systemwide (MODUS) Study.JMIR research protocols · 2025Article
- Cost-effectiveness of endovascular thrombectomy for acute ischemic stroke with established large infarct in Germany: a decision tree and Markov model.Journal of neurointerventional surgery · 2025Article
- A Markov model assessing the cost-effectiveness of various anti-vascular endothelial growth factor drugs and panretinal photocoagulation for the treatment of proliferative diabetic retinopathy.Eye (London, England) · 2025Article
- Effect modification and non-collapsibility together may lead to conflicting treatment decisions: A review of marginal and conditional estimands and recommendations for decision-making.Research synthesis methods · 2025Review
- Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning.PharmacoEconomics · 2024Article
- Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care.PharmacoEconomics · 2024Article
- An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity.The journal of headache and pain · 2024Article
- Guidance on the use of complex systems models for economic evaluations of public health interventions.Health economics · 2023Review
- Validating the Assumptions of Population Adjustment: Application of Multilevel Network Meta-regression to a Network of Treatments for Plaque Psoriasis.Medical decision making : an international journal of the Society for Medical Decision Making · 2023Article
- Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.Frontiers in public health · 2023Article
- Development and validation of an individual-based state-transition model for the prediction of frailty and frailty-related events.PloS one · 2023Article
- Cost-effectiveness of miglustat versus symptomatic therapy of Niemann-Pick disease type C.International journal of clinical pharmacy · 2022Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modelling in economic evaluation is an unavoidable fact of life. Cohort-based state transition models are most common, though discrete event simulation (DES) is increasingly being used to implement more complex model structures. The benefits of DES relate to the greater flexibility around the implementation and population of complex models, which may provide more accurate or valid estimates of the incremental costs and benefits of alternative health technologies. The costs of DES relate to the time and expertise required to implement and review complex models, when perhaps a simpler model would suffice. The costs are not borne solely by the analyst, but also by reviewers. In particular, modelled economic evaluations are often submitted to support reimbursement decisions for new technologies, for which detailed model reviews are generally undertaken on behalf of the funding body. This paper reports the results from a review of published DES-based economic evaluations. Factors underlying the use of DES were defined, and the characteristics of applied models were considered, to inform options for assessing the potential benefits of DES in relation to each factor. Four broad factors underlying the use of DES were identified: baseline heterogeneity, continuous disease markers, time varying event rates, and the influence of prior events on subsequent event rates. If relevant, individual-level data are available, representation of the four factors is likely to improve model validity, and it is possible to assess the importance of their representation in individual cases. A thorough model performance evaluation is required to overcome the costs of DES from the users' perspective, but few of the reviewed DES models reported such a process. More generally, further direct, empirical comparisons of complex models with simpler models would better inform the benefits of DES to implement more complex models, and the circumstances in which such benefits are most likely.
Indexed as
Identifiers
24627341What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.